Cargando…
cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma
Median survival of patients with glioblastoma (GBM) treated with standard of care which consists of maximal safe resection of the contrast-enhancing portion of the tumor followed by radiation therapy with concomitant adjuvant temozolomide (TMZ) remains 15 months. The tumor microenvironment (TME) is...
Autores principales: | Tripathi, Shashwat, Najem, Hinda, Mahajan, Akanksha Sanjay, Zhang, Peng, Low, Justin T, Stegh, Alexander H, Curran, Michael A, Ashley, David M, James, Charles David, Heimberger, Amy B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597127/ https://www.ncbi.nlm.nih.gov/pubmed/36324813 http://dx.doi.org/10.12688/f1000research.125163.1 |
Ejemplares similares
-
Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma
por: Boudreau, C. Elizabeth, et al.
Publicado: (2021) -
The cGAS Paradox: Contrasting Roles for cGAS-STING Pathway in Chromosomal Instability
por: Hong, Christy, et al.
Publicado: (2019) -
cGAS-STING pathway in cancer biotherapy
por: Wang, Yang, et al.
Publicado: (2020) -
The Use of Targeted Cytokines as Cancer Therapeutics in Glioblastoma
por: Sooreshjani, Moloud, et al.
Publicado: (2023) -
cGAS-STING pathway in oncogenesis and cancer therapeutics
por: Hoong, Brandon Yi Da, et al.
Publicado: (2020)